Large multi-center Phase 3 human clinical trials testing efficacy, absolute risk reduction, and adverse-event rates against placebo or active gold-standard comparators. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Tumour resections for TIL-IMP manufacture lead to limited surgical complications.
The results of the current clinical trial demonstrated that the use of applied to the skin MXF could be a potential option to expedite therapeutic laparoscopy-induced wound healing by reducing redness, oedema, ecchymosis, and...
CAS+IMD treatment of pregnant outpatients with COVID-19 showed similar safety, clinical outcomes and how the body absorbs the medicine profiles to that observed in non-pregnant adults.
Mepolizumab was effective and well-tolerated in patients with CRSwNP/ECRS from Japan, Russia, and China.
Upadacitinib 15/30 mg continued to be effective in treating clinical and functional outcomes in patients with RA.
Complications were similar among groups upholding the robotic technique to be safe.
The results of this study showed that Mucosamin spray was able to significantly improved radiation-induced oral mucositis in patients with oral squamous cell carcinoma.
Catvira did not impact hemoglobin levels while sofosbuvir + ribavirin showed significant decline in hemoglobin levels after 24 weeks (p < 0.05).
Fractions with large intrafraction motion were associated with increased toxicity and their.
In average, one complication occurred per surgery and the severity of complications were substantial.
Adjunctive perampanel (up to 12 mg/day) may be a suitable treatment for Chinese patients with FS, with/without FBTCS, or GTCS, with similar real-world benefits and safety/tolerability compared to non-Chinese patients.
The mean (SD) age of participants at baseline was 75.0 (7.9) years; 234 participants (59%) were women and 162 (41%) were men.
Sitagliptin/empagliflozin FDC doses achieved improvements in glycaemic control at 24 weeks, which was maintained through 52 weeks.
Conclusion This trial provides the first high-level evidence supporting the olanzapine-based four-drug combination to prevent CINV in GCT patients undergoing 5-day cisplatin-based chemotherapy.
In patients with non-histaminergic nC1INH angioedema, lanadelumab safety was consistent with previous studies; efficacy remained inconclusive due to unmet CASPIAN primary endpoint.
Brodalumab demonstrated sustained efficacy and a consistent safety profile in patients with axSpA over 68 weeks.
Results: Rates of concurrent full symptom relief of depressive and anxiety symptoms were higher with zuranolone versus placebo (P P P Conclusions: Zuranolone was associated with concurrent improvements in depressive and...
Veverimer was effective in treating metabolic acidosis in women with CKD, and significantly improved how they felt and functioned.
Results from the HELIOS-A RTE demonstrate relative stability with only modest changes in disease activity, sustained serum TTR reductions, and an acceptable safety profile with long-term vutrisiran treatment in patients.
Pretreatment transcriptome predicts first-year growth response in somapacitan-treated children with GHD.
The boron-based gel has a significant preventive effect on several categories of RD which might be used by clinicians in breast cancer.
The treatment effect of lenadogene nolparvovec on BCVA and vision-related quality of life observed 96 weeks (2 years) after treatment in RESCUE and REVERSE was sustained at 3 years in RESTORE, with a maximum follow-up of 52.
Once-daily HP 0.01% lotion was associated with significant reductions in disease severity in Hispanic participants with moderate-to-severe psoriasis, with good tolerability and safety over 8 weeks.
CLON-XR was efficacious and well tolerated in Chinese children and adolescents with ADHD, supporting its potential as a nonstimulant treatment option in this population.
Complete ER was higher in the NexoBrid versus the GV group (93% vs 4%; P 90% of burn patients, reduced surgery and blood loss.
GV1001 plus gemcitabine/capecitabine improved OS and TTP compared to gemcitabine/capecitabine alone in eotaxin-high patients with advanced PDAC.
Antimicrobial therapy in low risk afebrile neutropenic patients can be stopped early.
These results suggest that long-term treatment with anagrelide is not associated with adverse effects on cardiac function.
The lack of statistical significance on the primary endpoint was confounded by limitations of the RT-PCR assay.
The incidence of VRS ≥3 CRP was 33.3% (TNT) versus 20.0% (CRT) (P = .197).
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
